Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

Summary

The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses

Timeline

Start

2024-02-28

Primary completion

2025-06-17

Completion

2025-06-17

Drugs

Indications